Friedreich's AtaxiaPhase 2NCT00897221
A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia
A Phase 2 study testing Deferiprone oral solution 100mg/mL and Deferiprone oral solution 100 mg/mL in people with Friedreich's Ataxia, run by ApoPharma at 4 sites in 4 countries.
Trial summary
The primary objective of this study is to evaluate the long-term safety and tolerability of deferiprone in subjects with Friedreich's ataxia (FRDA). The secondary objective is to evaluate the long-term efficacy of deferiprone for the treatment of FRDA. Read more about this study
- Who is it for?
- Ages 7 to 35 years
- Conditions the study is for
- Friedreich's Ataxia
- What is being tested?
- Deferiprone oral solution 100mg/mL and Deferiprone oral solution 100 mg/mL
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 4 sitesin 4 countries
- Study dates
- Jun 2009to Mar 2011
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 7 to 35 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Subjects who completed the ApoPharma study LA29-0207
- Female subjects of childbearing potential must have a negative pregnancy test.
- Male subjects must confirm that he and/or his female partner will use an effective method of contraception for the length of the trial and for 30 days following completion of the study or early termination.
- Signed and witnessed written informed consent/assent, obtained prior to the first study intervention, as well as the ability to adhere to study restrictions, appointments and evaluation schedules.
Who cannot join
- Serum Ferritin and Hemoglobin (Hb) levels are below the reference range for age and sex-matched controls.
- Unable to complete T25FW AND with a score > 5 minutes in the 9HPT. Subjects who can complete T25FW or with a score ≤ 5 minutes in the 9HPT will be allowed to enrol).
- Doubling of score on 9HPT or T25FW compared to their study baseline results in LA29-0207.
- History or evidence of neutropenia/agranulocytosis defined by a confirmed absolute neutrophil count (ANC) < 1.5 x 109/L or thrombocytopenia defined by a platelet count <150 x 109/L.
- Occurrence of SAEs or any other AEs during the LA29-0207 study, which in the opinion of the investigator cause the patient's participation in the extension study to be inappropriate.
- Unable to comply with requirements of the protocol.
Show all 9Show fewer
- Pregnant, breastfeeding or planning to become pregnant during the study period.
- QTc interval >450ms.
- Have been on antioxidants prior to start of study treatment.
Trial locations and contacts
4 sites in 4 countries.
4 sites in 4 countries
About this study
Official title: An Open-label, Single Treatment, Safety and Efficacy, Long-term Study of Deferiprone in Subjects With Friedreich's Ataxia
The primary objective of this study is to evaluate the long-term safety and tolerability of deferiprone in subjects with Friedreich's ataxia (FRDA).
The secondary objective is to evaluate the long-term efficacy of deferiprone for the treatment of FRDA.
The tertiary objectives are to evaluate the effect of deferiprone on:
- cardiac function,
- quality of life, and
- functional status.
Read the detailed description
This is a multi-centre, open-label, non-randomized, single treatment, safety and efficacy study. All subjects who completed the LA29-0207 study are eligible for participation. Participants will receive deferiprone oral solution at the same dose (20 or 40 mg/kg/day) that they were assigned for LA29-0207. The duration of treatment will be 52 weeks.
- Conditions
- Friedreich's Ataxia
- Being tested
- Deferiprone oral solution 100mg/mL, Deferiprone oral solution 100 mg/mL
- Keywords
- Friedreich's ataxia
- Medical subject headings
- Friedreich Ataxia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Deferiprone oral solution 100mg/mLDrug
Also called Ferriprox
Deferiprone oral solution (20 mg/kg/day)
Deferiprone oral solution 100 mg/mLDrug
Also called Ferriprox
Deferiprone oral solution(40mg/kg/day)
| Study group | Role | What they receive |
|---|---|---|
| Dose 1 | Experimental | Deferiprone oral solution 20 mg/kg/day Receives: Drug: Deferiprone oral solution 100mg/mL |
| Dose 2 | Experimental | Deferiprone oral solution 40 mg/kg/day Receives: Drug: Deferiprone oral solution 100 mg/mL |
What is being measured
The primary outcome is the main question the study is designed to answer.
The patient's long-term tolerance of treatment will be assessed by the occurence of adverse events.
Measured: 52 weeks
Secondary outcomes (1)
The long-term efficacy of deferiprone will be assessed. Efficacy measures include the 9HPT, T25FW, LCLA, ICARS and FARS.
Measured: 52 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 May 2009 (estimated)
- Study startJun 2009
- Primary completionMar 2011
- Study completionMar 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Friedreich's AtaxiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- ApoPharma
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Massimo Pandolfo, M.D., Principal investigator, Hospital Erasme, Brussels, BelgiumArnold Munnich, M.D., Principal investigator, Hospital Necker-Enfants Malades, Paris, FranceFranco Taroni, M.D., Principal investigator, Fondazione IRCCS Istituto Neurologico "C. Besta", Milan, ItalyJavier Arpa, M.D., Principal investigator, La Fundaction Para la Investigacion Biomedica, Madrid, Spain
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00897221
- Sponsor's protocol ID
- LA29-EXT
- Status last verified
- Jun 2011
- First submitted
- 8 May 2009
- Last updated
- 27 Jun 2011
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 27 Jun 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Single Treatment, Safety and Efficacy, Long-term Study of Deferiprone in Subjects With Friedreich's Ataxia
- ClinicalTrials.gov ID
- NCT00897221
- Acronym / sponsor ID
- LA29-EXT
- Conditions
- Friedreich's Ataxia
- Keywords
- Friedreich's ataxia
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 36 participants (actual)
- Lead sponsor
- ApoPharmaIndustry (pharma, biotech, devices)
- Study start
- Jun 2009
- Primary completion
- Mar 2011 (actual)
- Study completion
- Mar 2011 (actual)
- First posted
- 12 May 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to evaluate the long-term safety and tolerability of deferiprone in subjects with Friedreich's ataxia (FRDA).
The secondary objective is to evaluate the long-term efficacy of deferiprone for the treatment of FRDA.
The tertiary objectives are to evaluate the effect of deferiprone on:
- cardiac function,
- quality of life, and
- functional status.
Detailed description
This is a multi-centre, open-label, non-randomized, single treatment, safety and efficacy study. All subjects who completed the LA29-0207 study are eligible for participation. Participants will receive deferiprone oral solution at the same dose (20 or 40 mg/kg/day) that they were assigned for LA29-0207. The duration of treatment will be 52 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dose 1 | Experimental | Drug: Deferiprone oral solution 100mg/mLDeferiprone oral solution 20 mg/kg/day |
| Dose 2 | Experimental | Drug: Deferiprone oral solution 100 mg/mLDeferiprone oral solution 40 mg/kg/day |
Who may qualify
- Ages
- 7 to 35 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (4 listed)
- Subjects who completed the ApoPharma study LA29-0207
- Female subjects of childbearing potential must have a negative pregnancy test.
- Male subjects must confirm that he and/or his female partner will use an effective method of contraception for the length of the trial and for 30 days following completion of the study or early termination.
- Signed and witnessed written informed consent/assent, obtained prior to the first study intervention, as well as the ability to adhere to study restrictions, appointments and evaluation schedules.
Key exclusion criteria (9 listed)
- Serum Ferritin and Hemoglobin (Hb) levels are below the reference range for age and sex-matched controls.
- Unable to complete T25FW AND with a score > 5 minutes in the 9HPT. Subjects who can complete T25FW or with a score ≤ 5 minutes in the 9HPT will be allowed to enrol).
- Doubling of score on 9HPT or T25FW compared to their study baseline results in LA29-0207.
- History or evidence of neutropenia/agranulocytosis defined by a confirmed absolute neutrophil count (ANC) < 1.5 x 109/L or thrombocytopenia defined by a platelet count <150 x 109/L.
- Occurrence of SAEs or any other AEs during the LA29-0207 study, which in the opinion of the investigator cause the patient's participation in the extension study to be inappropriate.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Deferiprone oral solution 100mg/mLAlso: FerriproxDeferiprone oral solution (20 mg/kg/day) | Drug | Dose 1 |
| Deferiprone oral solution 100 mg/mLAlso: FerriproxDeferiprone oral solution(40mg/kg/day) | Drug | Dose 2 |
Primary outcome
The patient's long-term tolerance of treatment will be assessed by the occurence of adverse events.
Time frame: 52 weeks
1 secondary outcome
The long-term efficacy of deferiprone will be assessed. Efficacy measures include the 9HPT, T25FW, LCLA, ICARS and FARS.
Time frame: 52 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jun 2011.
Related trials for Friedreich's Ataxia
RecruitingPhase 1
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
Friedreich's Ataxia (FA)
Active, not recruiting
Efficacy of Stabilometric Platform to Improve Standing Balance in Patients With Friedreich's Ataxia
Friedreich Ataxia
Recruiting
Electroencephalogram in Patients With Friedreich's Ataxia for the Study of the Structural and Functional Connectome.
Friedreich's Ataxia, Motor Disorders
Active, not recruitingObservational study
Characterisation of the Cognitive Profile of Patients Suffering From Friedreich's Ataxia
Friedreich Ataxia
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Massimo Pandolfo, M.D. principal investigator
Hospital Erasme, Brussels, Belgium
Arnold Munnich, M.D. principal investigator
Hospital Necker-Enfants Malades, Paris, France
Franco Taroni, M.D. principal investigator
Fondazione IRCCS Istituto Neurologico "C. Besta", Milan, Italy
4 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Deferiprone oral solution 100mg/mL and Deferiprone oral solution 100 mg/mL in people with Friedreich's Ataxia, run by ApoPharma at 4 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jun 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Belgium, France, Italy, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The patient's long-term tolerance of treatment will be assessed by the occurence of adverse events. (time frame: 52 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2011.